Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Raymond Press

Rheumatology San Diego, CA Medical Doctor

NPI 1215991302 CMS profile 236953

3965 5Th Ave, Ste 430, San Diego, CA 92103

Open in the dashboard

General payments

$16,545

714 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Raymond Press of San Diego, CA is reported in the CMS Open Payments database as having received $16,545 across 714 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $18 1
2023 General $125 2
2022 General $3,753 144
2021 General $3,629 161
2020 General $3,455 164
2019 General $5,564 242

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Raymond Press
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Raymond Press were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Raymond Press Rheumatology median Middle half National median
2019 $5,564 $744 $153–$2,687 $163
2020 $3,455 $462 $98–$2,027 $114
2021 $3,629 $531 $101–$2,153 $132
2022 $3,753 $627 $125–$2,303 $149
2023 $125 $741 $145–$2,524 $160
2024 $18 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amgen Inc. $2,233 88 payments
  2. Horizon Therapeutics plc $2,093 124 payments
  3. AbbVie, Inc. $1,312 46 payments
  4. GlaxoSmithKline, LLC. $1,299 38 payments
  5. Radius Health, Inc. $1,254 45 payments
  6. UCB, Inc. $1,088 46 payments
  7. Janssen Biotech, Inc. $826 56 payments
  8. Celgene Corporation $698 27 payments
  9. Mallinckrodt Hospital Products Inc. $683 23 payments
  10. Pfizer Inc. $595 27 payments
  11. Other $4,464 194 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $16,422 709 payments
  2. Education $123 5 payments
Products named General payments · program years 2019–2024
  1. Tymlos $1,254 45 payments
  2. BENLYSTA $1,184 37 payments
  3. Cimzia $996 45 payments
  4. KRYSTEXXA $930 42 payments
  5. SIMPONI ARIA $797 53 payments
  6. Otezla $746 39 payments
  7. RAYOS Rayos $727 52 payments
  8. STELARA $722 49 payments
  9. RAYOS Rayos $706 51 payments
  10. RAYOS Rayos $706 51 payments
  11. Other $12,285 584 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

714 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record